首页> 美国卫生研究院文献>Antimicrobial Agents and Chemotherapy >Comparative Efficacies of Four Amphotericin B Formulations—Fungizone Amphotec (Amphocil) AmBisome and Abelcet—against Systemic Murine Aspergillosis
【2h】

Comparative Efficacies of Four Amphotericin B Formulations—Fungizone Amphotec (Amphocil) AmBisome and Abelcet—against Systemic Murine Aspergillosis

机译:两种两性霉素B制剂(真菌剂两性霉素(Amphocil)AmBisome和Abelcet)对抗系统性小鼠曲霉病的比较功效

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

We compared various amphotericin B formulations (no treatment or 0.8 mg of Fungizone [conventional deoxycholate amphotericin B] per kg of body weight, or 0.8, 4, or 8 mg of Amphocil, AmBisome, or Abelcet per kg of body weight) for treatment of systemic murine aspergillosis. In two studies, all formulations prolonged survival, with the results for AmBisome nearly equivalent to those for Fungizone; Amphocil and Abelcet were less effective or equivalent depending on the severity of infection. No survivors were cured in both kidneys and brain, but each formulation showed efficacy, especially in the kidneys. Although higher doses could be given, no lipid-based formulation showed consistent superiority over Fungizone or over each other.
机译:我们比较了各种两性霉素B制剂(每千克体重未治疗或0.8 mg真菌类[常规脱氧胆酸盐两性霉素B],或每千克体重0.8、4或8 mg两性霉素,AmBisome或Abelcet)治疗全身性鼠曲霉病。在两项研究中,所有配方均延长了生存期,AmBisome的结果几乎与Fungizone的结果相同;根据感染的严重程度,两性霉素和Abelcet疗效较差或相当。肾脏和大脑均未治愈任何幸存者,但每种制剂均显示出疗效,尤其是在肾脏中。尽管可以给予更高的剂量,但没有任何基于脂质的制剂显示出优于Fungizone或彼此优于的一致优势。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号